Valeant Cesamet Slated To Hit Market In “Next Several Weeks”
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval comes with indication restricting use to patients who don’t respond to conventional antiemetics due to concern over “disturbing psychotomimetic reactions.”
You may also be interested in...
Valeant Plans New Sales Strategy For Cesamet; Ends Deal With Par
The two parties have terminated a marketing agreement for the anti-emetic based on a change in strategic priorities.
Valeant Plans New Sales Strategy For Cesamet; Ends Deal With Par
The two parties have terminated a marketing agreement for the anti-emetic based on a change in strategic priorities.
Cesamet Launch Will Highlight Longer Duration of Action Vs. Marinol
Valeant will also study the cannabinoid-receptor agonist in combination with other anti-emetics.